nilvadipine has been researched along with Hypertension in 49 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effect of a Ca antagonist (nilvadipine) on the occurrence or recurrence of symptomatic stroke in hypertensive patients with MRI-defined asymptomatic cerebral infarction (ACI), periventricular hyperintensity (PVH), and deep and subcortical white matter hyperintensity (DSWMH), with or without a history of stroke, and evaluated the effect of long-term treatment on the lesions." | 9.12 | Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment. ( Fukuuchi, Y; Hirai, S; Okudera, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2007) |
| "Because blood viscosity is significantly raised in patients with essential hypertension (EH), the hemorheological effects of a 4-month chronic treatment with the calcium antagonist nilvadipine (FK 235, 5-isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4- (m-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 75530-68-6) on elevated blood viscosity was investigated prospectively in patients with EH, and compared with those in normotensive individuals of similar age." | 9.08 | Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension. ( Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y, 1997) |
| "To investigate the 24-hour efficacy of nilvadipine (8 and 16 mg)in patients with mild to moderate essential hypertension, a double-blind, randomized, placebo-controlled, multicenter study with 3 parallel medication groups (placebo, 8, and 16 mg nilvadipine) was performed." | 9.08 | Nilvadipine in hypertension--experience in ambulatory treatment. ( Burkardt, I; Hoffmann, A; Kraul, H, 1997) |
| "QUERY: Influence of Nilvadipine, a new calcium channel blocker on the daytime blood pressure profile and 24-hour blood pressure values in patients with mild-to-moderate hypertension." | 9.07 | [Effect of nilvadipine on diurnal blood pressure profile. Use of a new calcium channel blocker in mild to intermediate hypertension]. ( Keck, M; Quitzdorff, G, 1992) |
| "61 outpatients suffering from essential hypertension with diastolic blood pressure adjusted to < or = 95 mmHg by nifedipine, and simultaneous lower-leg edema." | 9.07 | [Effect of nilvadipine on nifedipine-induced edema of the lower leg. Results of a double-blind randomized comparative study]. ( Schmitt, W; Vollmuth, M, 1994) |
| "Hypertension in an 83-year-old woman with early Alzheimer disease was treated with a calcium channel blocker, nilvadipine, for 3 months." | 7.74 | Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. ( Araki, N; Imabayashi, E; Kuji, I; Matsuda, H; Ohkubo, T; Shimazu, K, 2008) |
| "The protective effect of nilvadipine, a Ca2+ antagonist, on cerebral ischemia was investigated in spontaneously hypertensive rats." | 7.69 | Protective effect of nilvadipine on focal cerebral ischemia in spontaneously hypertensive rats. ( Fukasawa, H; Kawamura, S; Li, Y; Shirasawa, M; Yasui, N, 1996) |
| "The immediate haemodynamic effects of the calcium antagonist nilvadipine have been studied in ten patients with established mild essential hypertension." | 7.67 | Effect of the calcium antagonist nilvadipine on haemodynamics at rest and during cold stimulation in essential hypertension. ( Hashimoto, N; Hattori, N; Nakamura, S; Ohta, H; Satoh, S; Takabatake, T; Yamada, Y; Yamamoto, Y, 1987) |
| "Grade I hypertension was present in 53." | 6.90 | Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( Claassen, JAHR; de Heus, RAA; Donders, R; Lawlor, BA; Olde Rikkert, MGM; Santoso, AMM, 2019) |
| "Nilvadipine treatment lowered systolic blood pressure (Δ=-11." | 6.90 | Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. ( Claassen, JAHR; de Heus, RAA; de Jong, DLK; Donders, R; Günther, M; Lawlor, BA; Olde Rikkert, MGM; Rijpma, A; van Osch, MJP, 2019) |
| "Nilvadipine was well tolerated (only three patients were discontinued due to side effects)." | 6.67 | Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. ( Chen, CF; DeQuattro, V; Douglas, J; Saunders, E; Singh, S; Svetkey, LP; Vlachkis, ND; Weir, MR; Wiedl, SC; Woodward, DL, 1990) |
| "The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism." | 6.39 | Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995) |
| "Nilvadipine appears to be an effective hypotensive agent at single daily doses of 8 mg." | 5.28 | Nilvadipine in hypertension with renal dysfunction. ( Albert, FW; Berger, HH, 1992) |
| "Twelve patients with MCI and hypertension were randomly assigned to receive nilvadipine or amlodipine for 12-16 weeks." | 5.12 | Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. ( Abe, K; Hanyu, H; Hirao, K; Iwamoto, T; Koizumi, K; Shimizu, S, 2007) |
| "We examined the effect of a Ca antagonist (nilvadipine) on the occurrence or recurrence of symptomatic stroke in hypertensive patients with MRI-defined asymptomatic cerebral infarction (ACI), periventricular hyperintensity (PVH), and deep and subcortical white matter hyperintensity (DSWMH), with or without a history of stroke, and evaluated the effect of long-term treatment on the lesions." | 5.12 | Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment. ( Fukuuchi, Y; Hirai, S; Okudera, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2007) |
| "To evaluate the effect of a calcium antagonist, nilvadipine, on cerebral blood flow and oxygen metabolism, we prospectively examined five ischaemic stroke patients, with both hypertension and chronic major cerebral artery occlusion, using positron emission tomography." | 5.10 | Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. ( Kobayashi, M; Noda, A; Ogasawara, K; Ogawa, A; Yasuda, S; Yukawa, H, 2003) |
| "To evaluate the effects of cilnidipine (CNP), L- and N-type calcium channel blocker and nilvadipine (NVP) on 24-h urinary epinephrine (U-EP), norepinephrine (U-NE), dopamine (U-DA) and C-peptide (U-CPR) in patients associated with hypertension and non-insulin-dependent diabetes mellitus (HT-NIDDM), a randomized crossover study was performed with 35 HT-NIDDM patients." | 5.09 | Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. ( Hattori, Y; Irie, M; Takeda, S; Ueshiba, H, 1999) |
| "To investigate the 24-hour efficacy of nilvadipine (8 and 16 mg)in patients with mild to moderate essential hypertension, a double-blind, randomized, placebo-controlled, multicenter study with 3 parallel medication groups (placebo, 8, and 16 mg nilvadipine) was performed." | 5.08 | Nilvadipine in hypertension--experience in ambulatory treatment. ( Burkardt, I; Hoffmann, A; Kraul, H, 1997) |
| "Because blood viscosity is significantly raised in patients with essential hypertension (EH), the hemorheological effects of a 4-month chronic treatment with the calcium antagonist nilvadipine (FK 235, 5-isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4- (m-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 75530-68-6) on elevated blood viscosity was investigated prospectively in patients with EH, and compared with those in normotensive individuals of similar age." | 5.08 | Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension. ( Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y, 1997) |
| "This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension." | 5.08 | The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. ( Inoue, H; Oh-hashi, S; Takata, M; Tomita, S; Ueno, H; Yasumoto, K, 1997) |
| "In an open monocentric phase II study, 20 inpatients with hypertension were treated with a single daily dose of nilvadipine for 3 weeks after a 1-week placebo washout phase." | 5.07 | 24-hour blood pressure control after single daily doses of nivaldipine in patients with essential hypertension. ( Huber, HJ; Kuchlbauer, R; Lossnitzer, K; Quitzdorff, G, 1992) |
| "QUERY: Influence of Nilvadipine, a new calcium channel blocker on the daytime blood pressure profile and 24-hour blood pressure values in patients with mild-to-moderate hypertension." | 5.07 | [Effect of nilvadipine on diurnal blood pressure profile. Use of a new calcium channel blocker in mild to intermediate hypertension]. ( Keck, M; Quitzdorff, G, 1992) |
| "61 outpatients suffering from essential hypertension with diastolic blood pressure adjusted to < or = 95 mmHg by nifedipine, and simultaneous lower-leg edema." | 5.07 | [Effect of nilvadipine on nifedipine-induced edema of the lower leg. Results of a double-blind randomized comparative study]. ( Schmitt, W; Vollmuth, M, 1994) |
| "Hypertension in an 83-year-old woman with early Alzheimer disease was treated with a calcium channel blocker, nilvadipine, for 3 months." | 3.74 | Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. ( Araki, N; Imabayashi, E; Kuji, I; Matsuda, H; Ohkubo, T; Shimazu, K, 2008) |
| "The protective effect of nilvadipine, a Ca2+ antagonist, on cerebral ischemia was investigated in spontaneously hypertensive rats." | 3.69 | Protective effect of nilvadipine on focal cerebral ischemia in spontaneously hypertensive rats. ( Fukasawa, H; Kawamura, S; Li, Y; Shirasawa, M; Yasui, N, 1996) |
| "Antihypertensive efficacy of the calcium channel blocker, nilvadipine, was investigated in 21 patients with essential hypertension in relation to the intracellular sodium concentration ([Na]i) in erythrocytes and clinical variables, such as age, body weight, pretreatment blood pressure and plasma renin activity." | 3.68 | Erythrocyte sodium cannot predict hypotensive effects of calcium channel blockers. ( Ishibashi, K; Ishida, T; Ishida-Kainouchi, M; Kajiyama, G; Kanbe, M; Matsuura, H; Okura, Y; Oshima, T; Ozono, R; Watanabe, M, 1993) |
| "The immediate haemodynamic effects of the calcium antagonist nilvadipine have been studied in ten patients with established mild essential hypertension." | 3.67 | Effect of the calcium antagonist nilvadipine on haemodynamics at rest and during cold stimulation in essential hypertension. ( Hashimoto, N; Hattori, N; Nakamura, S; Ohta, H; Satoh, S; Takabatake, T; Yamada, Y; Yamamoto, Y, 1987) |
| "Nilvadipine treatment lowered systolic blood pressure (Δ=-11." | 2.90 | Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. ( Claassen, JAHR; de Heus, RAA; de Jong, DLK; Donders, R; Günther, M; Lawlor, BA; Olde Rikkert, MGM; Rijpma, A; van Osch, MJP, 2019) |
| "Grade I hypertension was present in 53." | 2.90 | Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( Claassen, JAHR; de Heus, RAA; Donders, R; Lawlor, BA; Olde Rikkert, MGM; Santoso, AMM, 2019) |
| "nilvadipine or terazosin was administered for 2 weeks in a randomized crossover manner." | 2.69 | Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke. ( Abe, I; Fujishima, M; Hasuo, Y; Nishino, Y; Onaka, U; Setoguchi, M, 1998) |
| "Nilvadipine was well tolerated (only three patients were discontinued due to side effects)." | 2.67 | Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. ( Chen, CF; DeQuattro, V; Douglas, J; Saunders, E; Singh, S; Svetkey, LP; Vlachkis, ND; Weir, MR; Wiedl, SC; Woodward, DL, 1990) |
| "The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism." | 2.39 | Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995) |
| "Nilvadipine is a new calcium antagonist of the the dihydropyridine group." | 2.39 | Nilvadipine: profile of a new calcium antagonist. An overview. ( Rosenthal, J, 1994) |
| "Nilvadipine appears to be an effective hypotensive agent at single daily doses of 8 mg." | 1.28 | Nilvadipine in hypertension with renal dysfunction. ( Albert, FW; Berger, HH, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.12) | 18.7374 |
| 1990's | 35 (71.43) | 18.2507 |
| 2000's | 8 (16.33) | 29.6817 |
| 2010's | 3 (6.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Heus, RAA | 3 |
| Olde Rikkert, MGM | 3 |
| Tully, PJ | 1 |
| Lawlor, BA | 3 |
| Claassen, JAHR | 3 |
| Donders, R | 2 |
| Santoso, AMM | 1 |
| de Jong, DLK | 1 |
| Rijpma, A | 1 |
| Günther, M | 1 |
| van Osch, MJP | 1 |
| Ogasawara, K | 1 |
| Noda, A | 1 |
| Yasuda, S | 1 |
| Kobayashi, M | 1 |
| Yukawa, H | 1 |
| Ogawa, A | 1 |
| Leonetti, G | 1 |
| Hanyu, H | 1 |
| Hirao, K | 1 |
| Shimizu, S | 1 |
| Iwamoto, T | 1 |
| Koizumi, K | 1 |
| Abe, K | 2 |
| Shinohara, Y | 2 |
| Tohgi, H | 1 |
| Hirai, S | 1 |
| Terashi, A | 1 |
| Fukuuchi, Y | 1 |
| Yamaguchi, T | 1 |
| Okudera, T | 1 |
| Matsuda, H | 1 |
| Araki, N | 1 |
| Kuji, I | 1 |
| Ohkubo, T | 1 |
| Imabayashi, E | 1 |
| Shimazu, K | 1 |
| Mitamura, T | 1 |
| Yamada, A | 1 |
| Ishida, H | 1 |
| Fujihira, S | 1 |
| Ohara, K | 1 |
| Noguchi, H | 1 |
| Mine, Y | 1 |
| Yoshida, H | 1 |
| Ayaori, M | 1 |
| Suzukawa, M | 1 |
| Hosoai, H | 1 |
| Nishiwaki, M | 1 |
| Ishikawa, T | 1 |
| Nakamura, H | 1 |
| Shimamoto, H | 1 |
| Shimamoto, Y | 1 |
| Brogden, RN | 1 |
| McTavish, D | 1 |
| Rosenthal, J | 1 |
| Vollmuth, M | 1 |
| Schmitt, W | 1 |
| Takakura, S | 1 |
| Furuichi, Y | 1 |
| Yamamoto, T | 1 |
| Ogawa, T | 1 |
| Satoh, H | 1 |
| Mori, J | 1 |
| Oshima, T | 1 |
| Matsuura, H | 1 |
| Ozono, R | 1 |
| Ishida-Kainouchi, M | 1 |
| Ishida, T | 1 |
| Ishibashi, K | 1 |
| Watanabe, M | 1 |
| Okura, Y | 1 |
| Kanbe, M | 1 |
| Kajiyama, G | 1 |
| Faust, G | 2 |
| Ueno, H | 2 |
| Takata, M | 2 |
| Oh-hashi, S | 2 |
| Tomoda, F | 1 |
| Yasumoto, K | 2 |
| Inoue, H | 2 |
| Kawamura, S | 2 |
| Li, Y | 2 |
| Shirasawa, M | 2 |
| Yasui, N | 2 |
| Fukasawa, H | 2 |
| Hoffmann, A | 1 |
| Kraul, H | 1 |
| Burkardt, I | 1 |
| Tsuda, Y | 1 |
| Satoh, K | 1 |
| Kitadai, M | 1 |
| Izumi, Y | 1 |
| Takahashi, T | 1 |
| Tomita, S | 1 |
| Yoshikawa, H | 1 |
| Ohta, A | 1 |
| Kasamatsu, K | 1 |
| Ueno, C | 1 |
| Funai, H | 1 |
| Kuse, S | 1 |
| Satani, O | 1 |
| Nakamura, N | 1 |
| Fukuda, K | 1 |
| Hano, T | 1 |
| Ueno, Y | 1 |
| Nishio, I | 1 |
| Iseki, Y | 1 |
| Setoguchi, M | 1 |
| Onaka, U | 1 |
| Abe, I | 2 |
| Hasuo, Y | 1 |
| Nishino, Y | 1 |
| Fujishima, M | 2 |
| Kawahara, J | 1 |
| Kashiwabara, T | 1 |
| Ogawa, N | 1 |
| Okada, Y | 1 |
| Izawa, T | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Seki, T | 1 |
| Adachi, C | 1 |
| Yoshimoto, T | 1 |
| Mishina, N | 1 |
| Imaki, T | 1 |
| Naruse, K | 1 |
| Demura, R | 1 |
| Demura, H | 1 |
| Takeda, S | 1 |
| Ueshiba, H | 1 |
| Hattori, Y | 1 |
| Irie, M | 1 |
| Kagawa, H | 1 |
| Nomura, S | 1 |
| Ozaki, Y | 1 |
| Nagahama, M | 1 |
| Fukuhara, S | 1 |
| Inouye, M | 1 |
| Mio, T | 1 |
| Sumino, K | 1 |
| Yasui-Furukori, N | 1 |
| Tateishi, T | 1 |
| Lossnitzer, K | 1 |
| Huber, HJ | 1 |
| Kuchlbauer, R | 1 |
| Quitzdorff, G | 2 |
| Keck, M | 2 |
| Fritschka, E | 1 |
| Berger, HH | 1 |
| Albert, FW | 1 |
| Pollack, KP | 1 |
| Kawai, K | 1 |
| Suzuki, S | 1 |
| Murayama, Y | 1 |
| Watanabe, Y | 1 |
| Yamashita, K | 1 |
| Tsuchihashi, T | 1 |
| Tsukashima, A | 1 |
| Matsumura, K | 1 |
| Tominaga, M | 1 |
| Nakao, Y | 1 |
| Kobayashi, K | 1 |
| Weir, MR | 1 |
| Vlachkis, ND | 1 |
| DeQuattro, V | 1 |
| Douglas, J | 1 |
| Svetkey, LP | 1 |
| Singh, S | 1 |
| Wiedl, SC | 1 |
| Chen, CF | 1 |
| Woodward, DL | 1 |
| Saunders, E | 1 |
| Yasujima, M | 1 |
| Kanazawa, M | 1 |
| Yoshida, K | 1 |
| Sato, M | 1 |
| Takeuchi, K | 1 |
| Tsunoda, K | 1 |
| Kudo, K | 1 |
| Kohzuki, M | 1 |
| Omata, K | 1 |
| Ohtsuka, M | 1 |
| Koibuchi, Y | 1 |
| Sakai, S | 1 |
| Tsujioka, K | 1 |
| Fujiwara, T | 1 |
| Ozaki, T | 1 |
| Maeda, K | 1 |
| Motoyama, I | 1 |
| Horiai, H | 1 |
| Ono, T | 1 |
| Takabatake, T | 1 |
| Yamamoto, Y | 1 |
| Nakamura, S | 1 |
| Hashimoto, N | 1 |
| Satoh, S | 1 |
| Yamada, Y | 1 |
| Ohta, H | 1 |
| Hattori, N | 1 |
| Mizuno, K | 1 |
| Hashimoto, S | 1 |
| Yabe, R | 1 |
| Kunii, N | 1 |
| Niimura, S | 1 |
| Tani, M | 1 |
| Watari, H | 1 |
| Fukuchi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for nilvadipine and Hypertension
| Article | Year |
|---|---|
[PICA study--hypertension and asymptomatic cerebral infarction].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Cerebral Infarcti | 2006 |
Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
Topics: Aging; Angina Pectoris; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular | 1995 |
Nilvadipine: profile of a new calcium antagonist. An overview.
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure; Calcium Channel Blockers; Cerebrov | 1994 |
24 trials available for nilvadipine and Hypertension
| Article | Year |
|---|---|
Blood Pressure Variability and Progression of Clinical Alzheimer Disease.
Topics: Aged; Alzheimer Disease; Antihypertensive Agents; Blood Pressure Determination; Cognition Disorders; | 2019 |
Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2019 |
Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cerebrovascular Circulation; D | 2019 |
Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Carotid Stenosis; Cerebrovascular Circulation; Femal | 2003 |
Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 2005 |
Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment.
Topics: Aged; Amlodipine; Antihypertensive Agents; Brain; Cerebrovascular Circulation; Cognition Disorders; | 2007 |
Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Cerebral Infarcti | 2007 |
Nilvadipine increases cerebral blood flow in elderly hypertensives: comparison with nifedipine.
Topics: Aged; Aging; Antihypertensive Agents; Aorta; Cerebrovascular Circulation; Compliance; Cross-Over Stu | 1995 |
[Nilvadipin for nifedipine induced calf edema. Results of a double blind randomized comparative study].
Topics: Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Double-Blind Method; Edema; Female; Hea | 1994 |
[Effect of nilvadipine on nifedipine-induced edema of the lower leg. Results of a double-blind randomized comparative study].
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans | 1994 |
[A one year study of single administration of nilvadipine. Results of the effectiveness and long-term tolerance in hypertension].
Topics: Aged; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hypertension; Long-Term Care; M | 1993 |
Time course of regression of vascular structural changes and its relation to cytosolic free calcium in hypertensives after nilvadipine treatment.
Topics: Adult; Aged; Analysis of Variance; Calcium; Calcium Channel Blockers; Cytosol; Female; Humans; Hyper | 1995 |
Nilvadipine in hypertension--experience in ambulatory treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Blood Pressure; Calcium Channel Blocker | 1997 |
Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension.
Topics: Blood Pressure; Blood Viscosity; Calcium Channel Blockers; Chronic Disease; Female; Hematocrit; Huma | 1997 |
The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial | 1997 |
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aging; Blood Pressure Monitoring, Ambulatory; | 1998 |
Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus.
Topics: Aged; C-Peptide; Calcium Channel Blockers; Catecholamines; Chromatography, High Pressure Liquid; Cro | 1999 |
24-hour blood pressure control after single daily doses of nivaldipine in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Administration | 1992 |
Comparison of the efficacy of nilvadipine and nitrendipine on circadian blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Double-Blind Method; Drug Administration | 1992 |
The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension.
Topics: Alanine Transaminase; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Tolerance; | 1992 |
Comparisons of once-daily nilvadipine with enalapril and diuretic in patients with essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug The | 1992 |
[Effect of nilvadipine on diurnal blood pressure profile. Use of a new calcium channel blocker in mild to intermediate hypertension].
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Female; Humans; Hypertensio | 1992 |
Comparison of the effects of nilvadipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins B; Blood Glucose; Blo | 1992 |
Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension.
Topics: Blood Pressure; Double-Blind Method; Drug Evaluation; Heart Rate; Humans; Hypertension; Multicenter | 1990 |
22 other studies available for nilvadipine and Hypertension
| Article | Year |
|---|---|
Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease.
Topics: Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Cerebrovascular Circulation; Cysteine | 2008 |
Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arterioles; Blood Urea Nitrogen; Creatinine; Hypertension; Ki | 1994 |
Effects of Ca-antagonists on oxidative susceptibility of low density lipoprotein (LDL).
Topics: Adult; Amlodipine; Apolipoproteins; Calcium Channel Blockers; Electrophoresis, Agar Gel; Fatty Acids | 1995 |
[Nilvadipine in the hypertensive elderly. Risk factor for cerebral insufficiency. Study report].
Topics: Aged; Antihypertensive Agents; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Humans; | 1993 |
Effect of nilvadipine on the development of neurological deficits in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Disorders; Eating; Hypertension; Male; Nifedipine | 1994 |
Erythrocyte sodium cannot predict hypotensive effects of calcium channel blockers.
Topics: Age Factors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Erythrocytes; Female | 1993 |
Protective effect of nilvadipine on focal cerebral ischemia in spontaneously hypertensive rats.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Cerebral Infarction; Dose-Response Relationship, | 1996 |
Enhanced efficacy of nilvadipine in hypertensives whose raised ambulatory blood pressure is sustained during sleep.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Female; Hum | 1998 |
Effects of treatment with nilvadipine on cerebral ischemia in rats.
Topics: Animals; Antihypertensive Agents; Brain; Calcium Channel Blockers; Cerebral Infarction; Hypertension | 1998 |
Antihypertensive properties of KRN4884, a novel long-lasting potassium channel opener.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Calcium Channel Blockers; Cromaka | 1999 |
Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Blotting, Southern; Brain; Calcium Channel Blockers; Cardiovascular | 1999 |
Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; CD4-CD8 Ratio; Collagen Diseases; Cytokines; | 1999 |
Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arteriosclerosis; Case-Control Studies; Cho | 2000 |
Carbamazepine decreases antihypertensive effect of nilvadipine.
Topics: Antihypertensive Agents; Antimanic Agents; Carbamazepine; Drug Interactions; Humans; Hypertension; M | 2002 |
Advances in antihypertensive treatment--profile of a new dihydropyridine. Proceedings of the 1st Nilvadipine Symposium. Munich, May 16, 1992.
Topics: Antihypertensive Agents; Humans; Hypertension; Nifedipine | 1992 |
Nilvadipine in hypertension with renal dysfunction.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Heart Rate; H | 1992 |
[Calcium antagonists have a favorable long-term effect on lipid metabolism. Dr. K. P. Pollack presents results of his studies. Interview by Christine Schaefer].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Lipids; Nifedipine | 1992 |
Ambulatory blood pressure monitoring in elderly hypertensives treated with the new calcium antagonist, nilvadipine.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Blood Pressure; Blood Pressure Determination; Calcium Chan | 1991 |
Calcium channel blockers reverse the sustained elevation of blood pressure induced by chronic infusion of endothelin in conscious rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Endothelins; Hypertension; Male | 1990 |
Effects of nilvadipine on the cardiovascular system in experimental animals.
Topics: Animals; Calcium; Calcium Channel Blockers; Coronary Disease; Coronary Vessels; Dogs; Female; Guinea | 1988 |
Effect of the calcium antagonist nilvadipine on haemodynamics at rest and during cold stimulation in essential hypertension.
Topics: Adult; Aged; Calcium Channel Blockers; Catecholamines; Cold Temperature; Female; Hemodynamics; Human | 1987 |
Antihypertensive effect of a new calcium channel blocker, FK 235, in essential hypertension.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hyperte | 1986 |